10 September 09:28
International
Mads Claus Rasmussen / AP / Profimedia
The Danish company Novo Nordisk has announced the layoff of 9,000 employees, following a restructuring aimed at generating annual savings of $1.26 billion. The company, which has become the most valuable in Europe due to demand for its medications, is facing increased competition that is affecting sales. The restructuring will also involve exceptional costs of 9 billion Danish crowns, but savings of 1 billion are expected in the fourth quarter. Novo's shares have dropped by 46% this year, and sales of weight loss medications could significantly increase in the next ten years.
Sources
Gigantul farmaceutic danez Novo Nordisk va renunța la 9.000 de angajați
Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition
Novo Nordisk, compania daneză care a creat cea mai vânată pastilă de slăbit din lume, are probleme. Gigantul pharma vrea să dea afara 9.000 de oameni după ce a început să piardă teren în lupta cu Eli Lilly, rivalul său american
Ozempic maker Novo Nordisk to cut 9,000 jobs amid increased competition
Ozempic giant Novo Nordisk to cut 9,000 jobs
Gigantul farma Novo Nordisk, cu afaceri în România, concediază 9.000 de angajaţi la nivel global
Ozempic-maker Novo Nordisk to cut 9,000 jobs